

Discovery of a benzamide derivative that protects pancreatic β -cells against endoplasmic reticulum stress

Hongliang Duan, Yu Li, Daleep K Arora, Depeng Xu, Hui-Ying Lim, and Weidong Wang

J. Med. Chem., **Just Accepted Manuscript** • Publication Date (Web): 22 Jun 2017

Downloaded from <http://pubs.acs.org> on June 22, 2017

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



1
2
3 **Discovery of a benzamide derivative that protects pancreatic β -cells against endoplasmic**
4
5 **reticulum stress**
6

7 Hongliang Duan,[†] Yu Li[‡], Daleep Arora[‡], Depeng Xu,[†] Hui-Ying Lim[#], and Weidong Wang^{†‡*}
8

9
10 [‡]Department of Medicine, Division of Endocrinology, The University of Oklahoma Health Science Center, 941
11 Stanton L. Young Blvd., Oklahoma City, Oklahoma 73104, United States
12

13
14 [†]Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma
15 City, Oklahoma 73104, United States
16
17

18
19 [#]Department of Physiology, The University of Oklahoma Health Science Center, 941 Stanton L. Young Blvd.,
20 Oklahoma City, Oklahoma 73104, United States
21
22

23
24
25 **ABSTRACT**
26

27
28
29 Endoplasmic reticulum (ER) stress-mediated pancreatic insulin-producing β -cell dysfunction and death
30 are critical elements in the onset and progression of both type 1 and type 2 diabetes. Here, through
31 cell-based high throughput screening we identified benzamide derivatives as a novel class of β -cell
32 protective agents against ER stress-induced dysfunction and death. Through structure-activity
33 relationship optimization, a 3-(*N*-piperidiny)methyl benzamide derivative **13d** markedly protects
34 β -cells against ER stress-induced dysfunction and death with near 100% maximum rescue activity and
35 an EC₅₀ value of 0.032 μ M. Compound **13d** alleviates ER stress in β -cells by suppressing ER
36 stress-mediated activation of all three branches of unfolded protein response (UPR) and apoptotic
37 genes. Finally, we show that **13d** significantly lowers blood glucose levels and increases concomitant
38 β -cell survival and number in a streptozotocin-induced diabetic mouse model. Identification of
39 β -cell-protective small molecules against ER stress provides a new promising modality for the
40 treatment of diabetes.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Diabetes, a group of metabolic diseases in which blood sugar levels are abnormally high over a prolonged period, has become a serious public health problem with tremendous social and economic burden on society; as of 2015, 415 million people were estimated to have diabetes worldwide.¹ The dysfunction and death of insulin-producing pancreatic β -cells are critical elements in the pathogenesis of type 1 (T1D) and type 2 (T2D) diabetes.^{2,3} Increasing evidence indicates that endoplasmic reticulum (ER) stress, a condition in which misfolded proteins accumulate in the ER, plays an important role in the decline in pancreatic β -cell function and mass in diabetes.^{4,5} Thus, prevention of functional β -cell death by targeting ER stress is a promising therapeutic approach for patients with diabetes. Unfortunately, no existing anti-diabetic drugs are capable of halting the progression of β -cell dysfunction and death.

In T2D, β -cells are forced to synthesize more insulin due to higher metabolic demands of obesity and insulin resistance, which typically exceeds the cellular capacity of the ER for protein folding, and eventually leads to ER stress and β -cell dysfunction and death.³ In addition, the common causes for β -cell dysfunction and death in T2D, including lipotoxicity, glucotoxicity, oxidative stress, amyloid deposition, and insulin mutations, have been known to be associated with unresolvable chronic ER stress.^{4,6,7} In T1D in which β -cells are destroyed by an auto-immune reaction, ER stress has also been implicated, and an ER stress-reducing chemical chaperone has been reported to prevent the onset of T1D in mouse models by protecting β -cell survival.⁸⁻¹⁰


ER stress induces activation of the unfolded protein response (UPR) through three ER membrane proteins, inositol-requiring protein 1 α (IRE1 α), PKR-like ER kinase (PERK), and activating

1
2 transcription factor 6 (ATF6), which act as unfolded protein sensors.^{4, 6, 11, 12} In unstressed cells, these
3
4 sensors are maintained in an inactive state through interaction with the protein chaperone binding
5
6 immunoglobulin protein (BiP). Under ER stress, unfolded and misfolded proteins accumulate in the ER
7
8 and bind to and sequester BiP, thereby releasing and activating the sensors.¹³ Upon initial or mild ER
9
10 stress, IRE1 α , PERK, and ATF6 each activate a series of events aimed at restoring ER homeostasis by
11
12 altering the translation, folding, and post-translational modification of secreted and membrane
13
14 proteins.^{11, 12, 14, 15} However, failure to adequately re-establish ER homeostasis eventually triggers cell
15
16 death, as in the case of chronic or severe ER stress.^{11, 12, 14-16}
17
18
19
20
21
22
23
24

25 Despite of the importance of ER stress in mediating β -cell dysfunction and death in the pathogenesis of
26
27 diabetes, only a handful of small molecules have so far been reported to exhibit β -cell-protective
28
29 activities against ER stress.^{17, 18} A major reason for the scarcity of β -cell-protective small molecules
30
31 could lie in the unique property of β -cells. β -cells normally produce and rapidly secrete insulin in
32
33 response to increases in blood glucose levels after food intake. To achieve this, they maintain a very
34
35 large pool of proinsulin mRNA (~20% of the total cellular mRNA) and increase proinsulin protein
36
37 synthesis 25-fold upon glucose stimulation.^{19, 20} This surge in proinsulin synthesis places a heavy
38
39 burden on the protein-folding capacity of the ER; β -cells are therefore particularly susceptible to ER
40
41 stress.⁶ This β -cell property may also in part explain why compounds that protect other cell types from
42
43 ER stress fail to protect β -cells.^{21, 22} Furthermore, the existing β -cell-protective small molecules^{17, 18} yet
44
45 still suffer from the issue of low potency, often with EC₅₀ values ranging from single- to double-digit
46
47 μ M.
48
49
50
51
52
53
54
55
56
57

58 In this study, we used a β -cell survival-based high throughput screening approach to identify small
59
60

1
2 molecules that protect β -cells against ER stress-induced apoptosis, and discovered
3
4
5 *N*-(3-chlorophenethyl)-2,3-dihydrobenzo[*b*][1,4]dioxine-6- carboxamide (**1**, Figure 1), a benzamide
6
7 derivative, as a β -cell-protective small molecule against ER stress, from ~50,000 compounds screened.
8
9
10 Although **1** is structurally novel, its weak activity on β -cell-protection (the maximum activity is 42%
11
12 with an EC₅₀ value at 21 μ M) prompted us to initiate a lead optimization campaign and a mechanistic
13
14 study on the β -cell-protection of this novel class of compounds.
15
16
17
18
19
20



21
22
23
24
25 **Compound 1,**


26 EC₅₀ = 21 μ M, Maximum activity = 42%

27
28
29
30 **Figure 1. Structure and cell protective effect on INS-1 cells of compound 1.**

31 32 33 34 35 **CHEMISTRY**


36
37
38 Synthetic routes for the preparation of the target compounds are summarized in Schemes 1-3. The
39
40 2-/3-/4-(*N*-piperidinyl)methyl benzoic acid methyl esters **6**, **4**, and **2**, were synthesized from the
41
42 corresponding bromomethylbenzoic acid methyl ester and piperidine. After a subsequent hydrolysis
43
44 step with sodium hydroxide, the (*N*-piperidinyl)methyl substituted esters were converted to the key
45
46 acid intermediates **7**, **5**, and **3**. Finally, condensation of these carboxylic acids with a series of
47
48 substituted benzylamines or phenylethylamines resulted in the desired compounds, **11a-d**, **12a-h**, and
49
50
51
52
53
54 **13a-d**.

Scheme 1. Synthesis of 4-(*N*-piperidinyl)methyl benzamide derivatives.^a




^aReagents and conditions: (i) piperidine, CH₂Cl₂, reflux, 75%; (ii) NaOH, MeOH/H₂O, rt, 87%; (iii) benzylamines or phenylethylamines, HATU, DIEA, CH₂Cl₂, rt, 70-80%.

Scheme 2. Synthesis of 3-(*N*-piperidinyl)methyl benzamide derivatives.^a



^aReagents and conditions: (i) piperidine, CH₂Cl₂, reflux, 71%; (ii) NaOH, MeOH/H₂O, rt, 83%; (iii) benzylamines or phenylethylamines, HATU, DIEA, CH₂Cl₂, rt, 75-85%.

Scheme 3. Synthesis of 2-(*N*-piperidinyl)methyl benzamide derivatives.^a





25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

^aReagents and conditions: (i) piperidine, K₂CO₃, THF, rt, 76%; (ii) NaOH, MeOH/H₂O, rt, 89%; (iii) 4-chlorobenzylamine, HATU, DIEA, CH₂Cl₂, rt, 73%.

Table 1. Activity of *N*-benzylbenzamide derivatives **8a-8h** on the survival of INS-1 cells treated with Tm.^a

Compd	R ₁	R ₂	Maximum activity (% rescue) ^a	EC ₅₀ (μM) ^b
1	3,4-	3-Cl	42% ± 12%	21 ± 5.7
8a	3,4-	H	47% ± 9%	19 ± 6.9
8b	3,4-	2-OMe	29% ± 6%	>30
8c	3,4-	4-F	50% ± 11%	21 ± 3.2
8d	3,4-	4-Cl	51% ± 17%	15 ± 1.6

1					
2					
3	8e		4-OMe	26% ± 8%	>30
4					
5					
6	8f		3,4-Di-OMe	5% ± 7%	>30
7					
8					
9					
10	8g		3-Cl	41% ± 14%	25 ± 5.2
11					
12					
13					
14	8h	3,4-Di-OMe	3-Cl	46% ± 17%	24 ± 2.1
15					
16					

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

^aMaximum activity value is reported as % rescue from Tm (0.1 μg/mL) -induced reduction of cell viability; the values for Tm treatment alone and control (DMSO, without Tm) treatment are designated as 0% and 100%, respectively in all tables. ^bEC₅₀ values (the concentrations that reach half-maximal activity) for INS-1 cell viability are calculated with GraphPad Prism from the data of ten 2-fold serial titration points in all tables. All experiments were performed in triplicate in all tables.


36 Results and Discussion

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A structure-activity-relationship (SAR) study was conducted to improve the weak potency of lead compound **1**. Newly synthesized or commercially available compounds were tested for their β-cell-protective activity against ER stress in rat INS-1 β-cells. Treatment of INS-1 β-cells with tunicamycin (Tm), a potent ER stress inducer that inhibits *N*-linked glycosylation of proteins and causes the accumulation of misfolded proteins, significantly reduced cell viability at 72 h compared with DMSO-treated cells, as measured by an intracellular ATP level-based cell viability assay (Figure 1A). The maximum activities and the concentrations that reach half-maximal activity (EC₅₀) of the compounds were evaluated by the degree of increase in viability of INS-1 cells co-treated with the

compounds in the presence of Tm compared with Tm treatment alone. Our initial focus was to explore the right phenyl ring of **1** while keeping the left dihydrobenzodioxine ring intact (Table 1). While removal of the 3-chloro group in the right phenyl ring of **1** (**8a**) did not markedly affect the EC₅₀ values and maximum activity levels of the resultant compound, the introduction of a methoxy group, such as 2-methoxy (**8b**), 4-methoxy (**8e**), and 3,4-dimethoxy (**8f**), led to less potency in that an increase in the EC₅₀ values and reduction in the maximum activity were observed compared to the parent compound **1**. However, replacement with 4-fluorine (**8c**) and 4-chlorine (**8d**) on the position 4 in the right phenyl ring appeared to improve the maximum activity levels of these compounds (42% for **1** to 50% for **8c** and 51% for **8d**) with a similar EC₅₀ values.


Table 2. Activity of *N*-benzylbenzamide derivatives **9a-9f** on the survival of INS-1 cells treated with Tm.



Compd	R	Maximum activity	
		(% rescue)	EC ₅₀ (μM)
9a	2-Cl	43% ± 12%	25 ± 6.9
9b	2-Br	38% ± 14%	25 ± 2.1
9c	3-Cl	57% ± 11%	9.5 ± 1.2
9d	3-Br	69% ± 9%	5.5 ± 0.7
9e	4-Cl	69% ± 12%	2.8 ± 0.5
9f	3,4-Di-Cl	68% ± 10%	3.6 ± 0.9

We then investigated the consequence of modifying the middle linker region, with the ethylene linker shortened to a methylene linker. We found that the methylene derivatives with modifications at position 2 (2-chlorine (**9a**) and 2-bromo (**9b**)) exhibited similar activity to that of hit compound **1**. However, the methylene derivatives with modifications at positions 3 and 4, such as 3-chlorine (**9c**), 3-bromo (**9d**), 4-chlorine (**9e**), and 3,4-di-chlorine (**9f**), exhibited significantly improved EC₅₀ values and maximum activity compared to the ethylene linker derivatives (Table 2 vs. Table 1). Of note, compound **9e** improved its EC₅₀ value over its ethylene counterpart **8d** by almost 6-fold (EC₅₀ 2.8 μM for **9e** vs. 15 μM for **8d**) and the maximum activity (69% for **9e** vs. 51% for **8d**). Thus, the methylene group appeared to be a preferable linker.

Table 3. Activity of *N*-phenethylbenzamide derivatives **10a-10p** on the survival of INS-1 cells treated with Tm.




Compd	R	Maximum activity	
		(% rescue)	EC ₅₀ (μM)
10a	2-Me	6% ± 5%	-
10b	2-S-iPr	30% ± 8%	>30
10c	3-F	<0	-
10d	3-NO ₂	<0	-
10e	3-NH ₂	<0	-

10f	3-OEt	49% ± 11%	26 ± 4.5
10g	3-NHSO ₂ Me	24% ± 8%	25 ± 2.1
10h	4-Me	25% ± 5%	20 ± 5.4
10i	4-O-propargyl	54% ± 8%	>30
10j	4SO ₂ -NMe ₂	37% ± 6%	19 ± 2.1
10k	4-(<i>N</i> -pyrrolidinyl)methyl	31% ± 7%	11 ± 1.9
10l	4-(<i>N</i> -piperidinyl)methyl	87% ± 9%	21 ± 3.5
10m	3,4-Di-Cl	42% ± 11%	17 ± 6.1
10n	3-Me-4-OMe	56% ± 8%	15 ± 3.2
10o	2,3,4-trifluoro	23% ± 6%	9.9 ± 2.1
10p	2,3,4,5-tetrafluoro	<0	-

Next, we shifted our SAR study to the left phenyl ring. Since removal of the 3-chloro group on the right ring did not affect the potency (**8a** vs. **1**), we kept the right phenyl ring unsubstituted. The resulting compounds with various substituents at the left phenyl ring are listed in Table 3. Most derivatives exhibited similar or reduced maximum activity or EC₅₀ values compared with the dihydrobenzodioxine derivative **8a**. However, the 4-(*N*-piperidinyl)methyl group derivative (**10l**) exhibited significantly improved maximum activity (87% for **10l** vs. 47% for **8a**) and a similar EC₅₀ value (21 μM for **10l** vs. 19 μM for **8a**). In contrast, introduction of a 4-(*N*-pyrrolidinyl)methyl group (**10k**) resulted in a reduced maximum activity (31%). Taken together, these results demonstrate that the 4-(*N*-piperidinyl)methyl group rendered favorable activity to the scaffold.

Table 4. Activity of 4-(*N*-piperidinyl)methyl benzamide derivatives **10l**, **11a-11d** on the survival of INS-1 cells treated with Tm.




Compd	n	R	Maximum activity	EC ₅₀
			(% rescue)	(μM)
10l	2	H	87% ± 6%	21 ± 3.5
11a	2	4-Cl	82% ± 10%	21 ± 4.2
11b	2	3,4-Di-Cl	71% ± 11%	24 ± 2.7
11c	1	4-Cl	77% ± 7%	9.5 ± 1.1
11d	1	3,4-Di-Cl	78% ± 10%	1.8 ± 0.2

As we observed more favorable activity of the methylene middle linker than ethylene derivatives in compounds with dihydrobenzodioxine ring for the left phenyl moiety, we investigated whether methylene middle linker exhibits similar advantage in the 4-(*N*-piperidinyl)methyl background. As summarized in Table 4, all the derivatives (**11a-11d**) exhibited significant maximum activity levels (all greater than 70%) regardless of the middle linker region. However, the derivatives with methylene middle linker exhibited significant improvements on the EC₅₀ values over the ethylene derivatives (**11c** vs. **11a** and **11d** vs. **11b**). In particular, the EC₅₀ value of methylene derivative with 3,4-di-chlorine substitution in the right phenyl ring (**11d**) improved by 13-fold compared to that of the corresponding

ethylene derivative **11b** (EC_{50} 1.8 μ M for **11d** vs. 24 μ M for **11b**). These results indicate that the combination of the 4-(*N*-piperidinyl)methyl moiety in the left phenyl ring and the methylene middle linker confers the compound favorable activity on β -cell protection.

Table 5. Activity of (*N*-piperidinyl)methyl benzamide derivatives **12a-12h**, **13a-d** on the survival of INS-1 cells treated with Tm.



Compd	Substitution position of (<i>N</i> -piperidinyl)methyl	R	Maximum activity (% rescue)	EC_{50} (μ M)
12a	2	4-Cl	73% \pm 13%	6.9 \pm 1.2
12b	3	H	95% \pm 8%	0.35 \pm 0.06
12c	3	2-Cl	93% \pm 7%	2.04 \pm 0.18
12d	3	3-Cl	90% \pm 11%	0.41 \pm 0.06
12e	3	4-Cl	93% \pm 13%	0.24 \pm 0.06
12f	4	2-Cl	87% \pm 15%	13 \pm 1.6
12g	4	3-Cl	80% \pm 9%	2.2 \pm 0.3
12h	4	3-Br	81% \pm 12%	4.9 \pm 0.7

13a	3	3-OMe	92% ± 10%	0.96 ± 0.16
13b	3	4-OMe	93% ± 5%	1.12 ± 0.21
13c	3	3-CF ₃	91% ± 14%	0.25 ± 0.04
13d	3	4-CF ₃	97% ± 8%	0.03 ± 0.01

We next investigated whether the position of (*N*-piperidiny)methyl group in the left phenyl ring affects β -cell-protective activity while keeping the methylene middle linker. A series of derivatives (**12a-12h**, **13a-13d**) were subsequently synthesized and these are summarized in Table 5. Clearly, substitution of (*N*-piperidiny)methyl group at position 3 (**12b-12e**) showed significant improvements over positions 2 and 4 (**12a**, and **12f-12h**) in both maximum activity and EC₅₀ values. Furthermore, we noticed that among the 3-(*N*-piperidiny)methyl derivatives (**12c-12e**), substitutions with chlorine at *meta* and *para* positions in the right-hand phenyl ring (**12d** and **12e**) improved the EC₅₀s over the ortho-substituted derivative **12c**. We finally examined whether the electron status in the right phenyl ring influences the potency on the 3-(*N*-piperidiny)methyl derivatives. We therefore substituted the compounds with the electron-donating group -OMe (**13a** and **13b**) and the electron-withdrawing group -CF₃ (**13c** and **13d**) at the meta- and para- positions on the right-hand phenyl ring. The electron-withdrawing groups, -CF₃ (**13c** and **13d**) and -Cl (**12d** and **12e**) at the meta- and para- positions significantly exhibited more favorable EC₅₀s compared to their electron-donating group (-OMe) counterparts (**13a** and **13b**). In particular, the compound with the substitution of the strong electron-withdrawing CF₃ in the para-position (**13d**) exhibited the most potent property with a near 100% maximum activity and an EC₅₀ at 0.032 μ M. We therefore chose **13d** for further characterization of its mechanism of action in promoting β -cell survival and function against ER stress.




Figure 1. Protective effects of **13d** on the viability of INS-1 cells after Tm treatment. (A, B) INS-1 cells were treated with or without Tm (0.1 μg/mL) in the presence of **13d** or DMSO for 72 h. Cell viability was determined by intracellular ATP assay (A) or MTT assay (B). (C) βTC6 cells were treated with or without Tm (0.3 μg/mL) in the presence of **13d** or DMSO for 72 h. The cell viability was determined by the intracellular ATP level. (D) INS-1 cells were treated with **13d** or DMSO for 72 h. The cell viability was determined by the intracellular ATP level. Results in A-C are expressed as the fold change compared with that of no Tm treatment (set to 1.0). The result in D is expressed as the fold-change compared to no 13d treatment (set to 1.0). Results in all panels are the means of 3 replicate wells and are representative of 3 independent experiments. Error bars indicate standard deviation (SD). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$ compared with Tm treated alone.

1
2
3
4
5
6
7
8 In the above SAR studies, we used the measurement of the intracellular ATP level as a surrogate assay
9
10 for cell viability. We observed that compound **13d** rescued the viability of INS-1 β -cells under Tm
11
12 treatment in a dose-dependent manner and that **13d** retained maximum β -cell-protective activity within
13
14 a wide range of concentrations from 0.16~20 μ M (Figure 1A). To confirm the authenticity of **13d**'s
15
16 protective effect on β -cell viability (not simply an increase in ATP-specific measurement), we used the
17
18 MTT assay, which measures the activity of NAD(P)H-dependent cellular oxidoreductase enzymes, as
19
20 an orthogonal method to measure cell viability. As shown in Figure 1B, Tm treatment reduced MTT
21
22 reading in INS-1 cells compared to that of DMSO treatment, and co-treatment with **13d** restored the
23
24 viability of INS-1 cells. To determine whether the protective effect of **13d** on β -cells is specific to
25
26 INS-1 cells, another β -cell line, β TC6, was used. As expected, Tm induced a reduction in viability in
27
28 β TC6 cells, and co-treatment with **13d** rescued the viability of β TC6 cells in a dose-dependent manner,
29
30 as assessed by the intracellular ATP level (Figure 1C). In addition, compound **13d** on its own had no
31
32 effect on β -cell viability in both cell lines (Figure 1C, 1D). Taken together, these results indicate that
33
34 compound **13d** protects β -cells against ER stress.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 2. Compound **13d** protects INS-1 cells against Tm-induced apoptosis. (A) INS-1 cells were treated with or without Tm (0.1 $\mu\text{g}/\text{mL}$) in the presence of **13d** at indicated concentrations or DMSO for 24 h. Cleaved caspase-3 and PARP were determined by Western blotting. α -Tubulin was used as a loading control. The data shown are representative of 3 independent experiments. (B) INS-1 cells were treated with or without Tm (0.1 $\mu\text{g}/\text{mL}$) in the presence of **13d** (0.1 μM) or DMSO for 48 h, and live-cell phase-contrast images were acquired (magnification 10 \times). The images shown are representative of 3 independent experiments. (C) TUNEL staining of INS-1 cells. INS-1 cells were treated with 0.1 $\mu\text{g}/\text{mL}$ of Tm with or without compound **13d** for 24 h before TUNEL staining. DAPI

1
2 was used as a nuclear marker. Magnification is 20×. The images shown are representative of 3
3
4 independent experiments. (D) Quantification of TUNEL staining from 20 fields of images. ** $P < 0.01$
5
6 compared with Tm treatment alone.
7
8
9

10
11
12 To determine whether the increase in β -cell viability following treatment with **13d** is caused by a
13
14 suppression of apoptotic cell death, several apoptosis-related makers were measured. First, levels of
15
16 cleaved caspase-3 and cleaved PARP were assayed by Western blotting. Caspase-3, a member of
17
18 executioner caspases activated by cleavage, plays essential roles in initiating apoptotic signaling and
19
20 executing the final stages of cell death, whereas the nuclear enzyme poly (ADP-ribose) polymerase
21
22 (PARP) plays an important role in a number of cellular processes involving DNA repair and cell death.
23
24 Under normal condition, caspase 3 exists as inactive proenzyme. However, upon severe ER stress,
25
26 caspase 3 undergoes proteolytic cleavage to produce two subunits that dimerize to form the active
27
28 enzyme, which in turns cleaves PARP. Hence, appearance of the cleaved forms of both caspase-3 and
29
30 PARP is an indication of apoptosis.^{23, 24} Tm treatment for 24 h significantly induced both cleaved
31
32 caspase-3 and cleaved PARP protein levels in INS-1 cells (Figure 2A). However, **13d** co-treatment
33
34 completely or significantly diminished Tm-induced cleavage of both caspase-3 and PARP (Figure 2A).
35
36 Consistent with this, significantly more viable INS-1 cells were observed with Tm and **13d**
37
38 co-treatment than with Tm alone (Figure 2B). A further assessment of apoptotic INS-1 cell death was
39
40 performed using TUNEL assays to detect nuclear DNA fragmentation (a consequence of cell apoptosis)
41
42 in situ. Tm treatment resulted in a significant increase in TUNEL-positive cells (7% TUNEL-positive
43
44 cells compared to less than 0.2% in control group), while co-treatment with Tm and **13d** remarkably
45
46 reduced the TUNEL-positive cells (0.5%) (Figures 2C and 2D). Taken together, these results
47
48
49
50
51
52
53
54
55
56
57
58
59
60

demonstrate that **13d** can suppress Tm-induced β -cell apoptosis.



1
2
3
4
5 **Figure 3.** Compound **13d** reversed Tm-suppressed β -cell dysfunction. (A-D) INS-1 cells were treated
6 with or without Tm (0.1 $\mu\text{g}/\text{mL}$) in the presence of **13d** at indicated concentrations or DMSO for 24 h.
7
8 The mRNA levels of INS1 (A), INS2 (B), PDX1 (C), and MafA (D), were analyzed by qRT-PCR.
9
10 Relative mRNA levels were normalized against the housekeeping gene Cyclophilin A using the
11 comparative CT method. The results are the means of 3 replicate wells and are representative of 3
12 independent experiments. * $P < 0.05$ and ** $P < 0.01$ compared with Tm treatment alone. Bars indicate
13 SD. (E) Insulin secretion by INS-1 cells incubated with 1.7 mM and 20 mM glucose in the presence or
14 absence of Tm (0.1 $\mu\text{g}/\text{mL}$) and **13d**. Secreted insulin was measured by ELISA after 24 h treatment. *
15 $P < 0.05$. The amount of insulin secreted in response to 1.7 mM glucose in the absence of Tm was set
16 to 1.0 and was normalized with total protein concentration.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 In addition to β -cell apoptosis, ER stress also leads to β -cell dysfunction, namely, the impairment of
38 biosynthesis and secretion of insulin. First, we examined whether compound **13d** reverses the
39 Tm-suppressed mRNA levels of insulin genes. As expected, Tm treatment of INS-1 cells decreased the
40 mRNA levels of both insulin genes, INS1 and INS2, but this reduction was completely rescued by **13d**
41 (Figures 3A and 3B). Second, we examined whether compound **13d** affects the expression of β -cell
42 transcription factors PDX1 and MafA, which control β -cell identity and the expression of insulin
43 genes.^{25, 26} Tm treatment decreased the levels of PDX1 and MafA mRNA expression levels in INS-1
44 cells, however, these decreases were completely rescued by **13d** co-treatment (Figures 3C and 3D).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

secretion (GSIS). As shown in Figure 3E, Tm treatment abolished the insulin secretion caused by high concentration of glucose treatment (20 mM) in INS-1 cells. Addition of **13d** significantly rescued the GSIS in Tm-treated cells. Taken together, these data demonstrate that **13d** restores ER stress-impaired β -cell survival and function.




Figure 4. Compound **13d** inhibits Tm-induced ATF4 and CHOP up-regulation in INS-1 cells. (A, B) INS-1 cells were treated with or without Tm (0.1 μ g/mL) in the presence of **13d** or DMSO for 8 h. ATF4 (A) and CHOP (B) mRNA levels were analyzed by qRT-PCR. Relative mRNA levels were normalized against the housekeeping gene Cyclophilin A using the comparative CT method. The

1
2 results were expressed as the fold-increase over mRNA levels in untreated control cells and are the
3
4 means of 3 replicate wells and representative of 3 independent experiments. ** $P < 0.01$ compared
5
6 with Tm treatment alone. Bar indicates SD. (C-E) INS-1 cells were treated with or without Tm (0.1
7
8 $\mu\text{g/mL}$) in the presence of **13d** or DMSO for 8 h. ATF4 and CHOP protein levels were determined by
9
10 Western blotting (C). α -Tubulin was used as an internal control. Quantification of ATF4 (D) and CHOP
11
12 (E) protein levels was analyzed by ImageJ program, which was normalized by α -Tubulin protein level.
13
14
15
16
17
18 The data shown are representative of 3 independent experiments.
19
20
21
22
23

24 Having established that compound **13d** restores ER stress-impaired β -cell survival and function, we
25
26 next investigated the mechanism of action by which **13d** protects β -cells against ER stress. Chronic or
27
28 severe ER stress activates all three branches of the UPR, PERK, IRE1 α , and ATF6, leading to eventual
29
30 cell death. First, we determined the effect of **13d** on the activation of the PERK pathway in β -cells
31
32 under ER stress. PERK activation phosphorylates eukaryotic translation initiator factor 2 α (eIF2 α),
33
34 which in turn allows for the up-regulation of activating transcription factor 4 (ATF4) and of the
35
36 pro-apoptotic gene C/EBP-homologous protein (CHOP).^{4, 8, 11, 27} Thus, we used ATF4 and CHOP
37
38 expression levels as markers of PERK pathway activation. Tm treatment of INS-1 cells significantly
39
40 increased the mRNA levels of both ATF4 and CHOP, whereas co-treatment with **13d** almost
41
42 completely abolished the Tm-induced increase in both mRNA levels (Figures 4A and 4B). In addition,
43
44 after treatment with Tm for 8 h, CHOP mRNA level increased 7-fold compared with the control group,
45
46 and co-treatment with compound **13d** inhibited Tm-induced CHOP expression with an IC₅₀ value of
47
48 0.037 μM (Figure 4C). Moreover, this IC₅₀ value was almost equal to the EC₅₀ value of **13d** for cell
49
50 survival (Table 5). In addition, **13d** had no effect on the mRNA levels of ATF4 and CHOP on its own
51
52
53
54
55
56
57
58
59
60

(Figure 4A and 4B). These results indicate that **13d** inhibits the activation of PERK-ATF4-CHOP pathway of the UPR under ER stress.




Figure 5. Compound **13d** inhibits Tm-induced XBP1s mRNA expression in INS-1 cells. INS-1 cells were treated with or without Tm (0.1 μg/mL) in the presence of **13d** or DMSO for 8 h. (A) XBP1s mRNA levels were analyzed by qRT-PCR. Relative mRNA levels were normalized against the housekeeping gene Cyclophilin A using the comparative CT method. ** $P < 0.01$ compared with Tm treatment alone. Bars indicate SD. (B) XBP1 mRNA levels were analyzed by RT-PCR and the products were resolved by agarose gel electrophoresis. The full-length (unspliced, XBP1u) and spliced (XBP1s) forms of XBP1 mRNA are indicated. Cyclophilin A mRNA was used as a loading control. Quantification was analyzed by ImageJ program shown at the bottom. The data shown are representative of 3 independent experiments.

Next, we determined the effect of **13d** on the activation of IRE1α in β-cells under ER stress. Activation

of the IRE1 α leads to cleavage of X-box binding protein-1 (XBP1) mRNA and this generates a spliced form (XBP1s) that is translated into a potent transcription factor that controls the expression of UPR genes involved in ER protein folding and degradation.^{6, 12, 27} We therefore used XBP1 splicing as a marker for the activation of the IRE1 α pathway and determined the effect of **13d** on IRE1 α -mediated XBP1 splicing in INS-1 cells in the presence of Tm. As shown in Figure 5A, Tm markedly increased the level of XBP1s mRNA in INS-1 cells, but this increase was abolished by **13d** co-treatment, as measured by qRT-PCT using XBP1 splicing-specific primers. Similarly, an electrophoretic separation of spliced and unspliced forms of XBP1 after RT-PCR amplification of total XBP1 mRNA revealed that **13d** inhibits the Tm-induced generation of XBP1s mRNA (Figure 5B). These results indicate that **13d** inhibits Tm-induced activation of IRE1 α -XBP1 pathway.





Figure 6. Compound **13d** decreases Bip and GRP94 mRNA levels induced by Tm. INS-1 cells were treated with or without Tm (0.1 μ g/mL) in the presence of **13d** or DMSO for 8 h. Bip (A) and GRP94 (B) mRNA levels were analyzed by qRT-PCR. Relative mRNA levels were normalized against the housekeeping gene Cyclophilin A using the comparative CT method. The results are the means of 3

1
2 replicate wells and representative of 3 independent experiments. ** $P < 0.01$ compared with Tm
3
4 treatment alone. Error bars indicate SD.
5
6
7
8
9

10 We then investigated the effects of **13d** on the activation of ATF6 in β -cells under ER stress. Activated
11 ATF6 acts as a homodimer or as an ATF6–XBP1s heterodimer to control the up-regulation of select
12 UPR target genes including the chaperone proteins BiP and GRP94.^{12, 27} Therefore, these two
13 chaperone proteins were evaluated in the INS-1 cells in the presence of Tm. Both Bip and GRP94
14 mRNAs were up-regulated by treatment with Tm, while co-treatment with Tm and compound **13d**
15 almost completely reversed these increases (Figure 6A and 6B).
16
17
18
19
20
21
22
23
24
25
26
27
28

29 Thus far, our observation that **13d** protected β -cells against ER stress-induced cell death and
30 dysfunction and that **13d** inhibited ER stress-mediated activation of all three UPR pathways revealed a
31 strong correlation between the β -cell protective effect of **13d** and its suppression of ER stress response.
32
33 If **13d** protects β -cells through the inhibition of ER stress response, a structurally similar but
34 β -cell-inactive analog of **13d** would be expected to possess no inhibitory effect on ER stress-induced
35 UPR response. Indeed, we observed that as a negative control, the β -cell-inactive analog **8f** had no
36 effect on the UPR pathways. As shown in Figure 7, **8f** co-treatment had no obvious effect on the
37 mRNA levels of ATF4, CHOP, Bip, GRP94 or XBP1s. These results together support the notion that
38
39
40
41
42
43
44
45
46
47
48
49
50 **13d** protects β -cell survival by alleviating ER stress.
51
52
53
54
55
56
57
58
59
60



1
2 **Figure 7.** Inactive compound **8f** does not decrease ER stress related mRNA levels induced by Tm.

3
4
5 INS-1 cells were treated with or without Tm (0.1 $\mu\text{g/mL}$) in the presence of **8f** or DMSO for 8 h. ATF4

6
7 (A), CHOP (B), Bip (C), GRP94 (D), and XBP1s (E) mRNA levels were analyzed by qRT-PCR.

8
9
10 Relative mRNA levels were normalized against the housekeeping gene Cyclophilin A using the

11
12 comparative CT method. The results are the means of 3 replicate wells and representative of 3

13
14
15 independent experiments. Error bars indicate SD.

16
17
18
19
20 We next evaluated the *in vivo* efficacy of **13d** using a streptozotocin (STZ)-induced diabetic mouse

21
22 model. STZ induces ER stress in β -cells in addition to the increase in reactive oxygen species (ROS)

23
24 production and DNA alkylation.^{28, 29} C57BL/6 mice injected intraperitoneally with low dose STZ (50

25
26 mg/kg) once daily for 5 consecutive days develop diabetes; blood glucose levels increased gradually

27
28
29 within a week of STZ treatment. Co-treatment with **13d** (5 mg/kg) lowered the glucose levels

30
31 significantly in a time-dependent manner (314 mg/dL (**13d**) vs. 422 mg/dL (vehicle) after 3 weeks of

32
33 treatment) (Figure 8A). The intraperitoneal glucose tolerance testing on overnight fasted animals

34
35 showed lower blood glucose levels at 15, and 30 min in mice co-treated with STZ and **13d**, compared

36
37 to vehicle-treated STZ group (Figure 8B).

38
39
40 To evaluate whether **13d** treatment influences the survival of β -cells in STZ animals, histology on

41
42 pancreatic sections was analyzed. We observed that **13d**-treated mice had more than double the total

43
44 pancreatic islet β -cell area compared to vehicle-treated mice ($67.4 \pm 5.9\%$ for STZ + **13d** vs. $30.2 \pm 7.9\%$

45
46 for STZ + saline, Figures 8C and 8D). In addition, **13d** had no obvious effect on the average number of

47
48 α -cells between vehicle and **13d** groups (Figure 8C). These results indicate that **13d** ameliorates

STZ-induced diabetes in mice by preserving β -cell survival.




Figure 8. Anti-diabetic effect of **13d** in the STZ-induced diabetic mouse model. (A) Fasting blood glucose levels were measured in STZ-injected mice treated with vehicle control ($n = 6$) or **13d** ($n = 7$). C57BL/6J mice were injected intraperitoneally once daily for 5 days with STZ (50 mg/kg body weight)

1
2 and with either vehicle ($n = 6$ mice) or **13d** (5 mg/kg body weight; $n = 7$ mice). Injections of vehicle or
3
4 **13d** alone were then continued for 2 more weeks. (B) Glucose tolerance test. Blood glucose levels
5
6 measured at indicated time points after intraperitoneal injection of glucose (2g/kg body weight). (C)
7
8 Pancreases were sectioned and slides were stained with anti-insulin antibody (green, β -cell marker),
9
10 anti-glucagon antibody (red, α -cell marker), and DAPI (blue). Slides were imaged with an Olympus
11
12 FV1000 confocal microscope. Representative images are shown in (C). (D) Quantification of total islet
13
14 area per section and β -cell number per islet. Total area of all islets per section calculated for a total of
15
16 six sections using insulin-positive cells to demarcate islets. Data are the means \pm SEM of six sections
17
18 from three mice. * $p < 0.05$ ** $p < 0.01$, and *** $p < 0.001$ by Student's t-test.
19
20
21
22
23
24
25
26
27
28

29 **Conclusion**

30
31 We discovered and optimized 3-(*N*-piperidinyl)methyl benzamide derivatives as potent agents that
32
33 suppress ER stress-induced β -cell death and dysfunction. Our lead optimization has led to the
34
35 identification of the 3-(*N*-piperidinyl)methyl benzamide analog **13d** with near 100% β -cell-protective
36
37 activity and an EC_{50} of 0.032 μ M against ER stress. Importantly, we showed that **13d** significantly
38
39 lowers blood glucose levels and increases β -cell survival in an STZ-induced diabetic mouse model. In
40
41 addition, we demonstrated that **13d** alleviates ER stress/UPR response by inhibiting Tm-induced
42
43 up-regulation of all three branches of unfolded protein response (UPR) and apoptosis. Figure 9
44
45 proposes a model of signaling events leading to the protective effect of **13d** in β -cells against ER
46
47 stress-induced dysfunction and cell death.
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 9. Proposed model of signaling pathways involved in **13d**-mediated β -cell-protective effects against ER stress. ER stress induces activation of three branches of UPR (ATF6, IRE1 α , and PERK), leading to up-regulation of Bip, GRP94, XBP1s, ATF4, and CHOP. These events result in the reduction in the expression of PDX1, MAFA and insulin genes, leading to β -cell dysfunction, and the eventual activation of caspase 3 and cell apoptosis. Compound **13d** protects β -cells against ER stress-mediated dysfunction and death by attenuating ER stress through up-regulating PDX1, MAFA and insulin genes and down-regulating ATF4, XBP1s, Bip, GRP94, CHOP, and caspase 3.

Our current work has unraveled compound **13d** as a representative of a new β -cell-protective chemotype containing a 3-(*N*-piperidinyl)methyl benzamide skeleton with a near 100% maximum protection activity and an EC₅₀ value of \sim 30 nM. Studies on the pharmacokinetic properties of **13d** are ongoing as part of our program to develop novel chemotypes as β -cell-protective leads for further anti-diabetic drug development.

EXPERIMENTAL SECTION

1. Chemistry

The reagents were purchased and used without further purification. ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker AC300 or a Bruker AC400 NMR spectrometer with tetramethylsilane as an internal reference. ESI-MS spectra were obtained on a Krats MS 80 mass spectrometer. Column chromatography was performed on silica gel (200–300 mesh). The purity of synthesized final compounds was determined by HPLC. Compounds **1**, **8a-h**, **9a-f**, and **10a-p** were purchased from ChemBridge. The structures and purities were confirmed using NMR and HPLC. The purities of all these compounds are more than 95%.

General procedure for compounds **3**, **5** and **7**. After the bromomethylbenzoic acid methyl ester (1 mmol) was dissolved in 4 mL of THF, piperidine (119 μL , 1.2 mmol) and K_2CO_3 (276 mg, 2 mmol) were added to the solution. The mixed solution was stirred at room temperature until the reaction was completed. The solution was poured into water (10 mL) and extracted with ethyl acetate (10 mL \times 3). The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford the desired (*N*-piperidinyl)methyl benzoic acid methyl esters **2**, **4** and **6**. The crude ester was added to a mixed solution of H_2O (2 mL) and methanol (2 mL) with sodium hydroxide (60 mg, 1.5 mmol). The solution was stirred at room temperature overnight. After the methanol was evaporated under vacuum, the pH of the residue aqueous layer was adjusted to 5. The formed precipitate was filtered, washed with cold water, and dried under vacuum to afford the desired product. 4-(*N*-piperidinyl)methyl benzoic acid (**3**). The title compound was obtained as a white solid from 4-bromomethyl benzoic acid methyl ester in 65% yield.²⁹

1
2 3-(*N*-piperidinyl)methyl benzoic acid (**5**) The title compound was obtained as a white solid from
3
4 3-bromomethyl benzoic acid methyl ester in 59% yield. ¹H NMR (400 MHz, DMSO-d₆): δ 10.78 (s,
5
6 1H), 8.17 (s, 1H), 8.01 (m, 2H), 7.59 (m, 1H), 4.35 (s, 2H), 3.32 (m, 2H), 3.17 (m, 2H), 2.53 (s, 2H),
7
8 1.80 (m, 6H).
9

10
11
12 2-(*N*-piperidinyl)methyl benzoic acid (**7**) The title compound was obtained as a white solid from
13
14 2-bromomethyl benzoic acid methyl ester in 68% yield. ¹H NMR (400 MHz, CDCl₃): δ 8.18 (dd, 1H,
15
16 *J* = 6.0, 1.2 Hz), 7.46 (m, 1H), 7.40 (m, 1H), 7.15 (d, *J* = 6.0 Hz), 3.84 (s, 2H), 3.15 (m, 2H), 2.36 (m,
17
18 2H), 1.82 (m, 2H), 1.60 (m, 4H).
19
20

21
22
23
24 General procedure for compounds **11a-11f**, **11i-11j**, and **12a-12h**. To a solution of compound **3**, **5** or **7**
25
26 (1 mmol) in anhydrous dichloromethane (5 mL), corresponding benzylamines or phenylethylamines
27
28 (1.2 mmol), HATU (1.5 mmol), and DIEA (2mmol) were added. The mixed solution was stirred at
29
30 room temperature. After the reaction was completed, H₂O (5 mL) was added to the solution. The
31
32 organic layer was separated and washed with brine, dried over anhydrous sodium sulfate, filtered,
33
34 concentrated, and purified by flash column chromatography to afford the desired product.
35
36
37

38
39
40 (**11a**). The title compound was obtained as a solid from **3** and 4-chlorophenylethylamine according to
41
42 the general procedure in 61% yield. ¹H NMR (400 MHz, DMSO-d₆): δ 8.53 (s, 1H), 7.89 (m, 2H),
43
44 7.42 (m, 2H), 7.35 (m, 2H), 7.26 (m, 2H), 3.48 (m, 4H), 2.84 (m, 2H), 2.43 (m, 2H), 1.54-1.24 (m, 8H).
45
46

47 ¹³C NMR (100 MHz, DMSO-d₆): δ 166.41, 139.07, 131.20, 131.03, 128.69, 127.61, 52.83, 34.80.
48

49 LC-MS (ESI⁺): 357 (M + H)⁺.
50

51
52
53 (**11b**). The title compound was obtained as a solid from **3** and 3,4-dichlorophenylethylamine according
54
55 to the general procedure in 81% yield. ¹H NMR (400 MHz, DMSO-d₆): δ 9.52 (br, 1H), 8.58 (m, 1H),
56
57 7.83 (m, 2H), 7.54 (m, 4H), 7.24 (m, 1H), 4.25 (s, 2H), 3.52 (m, 2H), 2.86 (m, 3H), 1.75-.163 (m, 7H).
58
59
60

¹³C NMR (100 MHz, DMSO-d₆): δ 141.36, 131.25, 131.22, 130.80, 129.73, 129.16, 127.78, 34.38.

LC-MS (ESI⁺): 391 (M + H)⁺.

(11c). The title compound was obtained as a solid from **3** and 4-chlorobenzylamine according to the general procedure in 78% yield. ¹H NMR (400 MHz, DMSO-d₆): δ 9.02 (br, 1H), 7.84 (m, 2H), 7.60 (m, 3H), 7.38 (m, 6H), 4.46 (s, 2H), 3.47 (m, 2H), 2.31 (m, 2H), 1.49-1.39 (m, 6H). ¹³C NMR (100 MHz, DMSO-d₆): δ 166.61, 139.30, 131.72, 129.54, 129.03, 128.67, 127.62, 54.36, 42.44, 26.00, 23.89. LC-MS (ESI⁺): 343 (M + H)⁺.

(11d). The title compound was obtained as a solid from **3** and 3,4-dichlorobenzylamine according to the general procedure in 63% yield. ¹H NMR (400 MHz, DMSO-d₆): δ 9.78 (br, 1H), 9.23 (m, 1H), 7.97 (m, 2H), 7.60 (m, 3H), 7.32 (m, 1H), 4.48 (s, 2H), 4.33 (s, 2H), 2.90 (s, 2H), 1.78-1.24 (br, 6H). ¹³C NMR (100 MHz, DMSO-d₆): δ 166.18, 141.32, 131.70, 131.33, 130.97, 129.79, 129.74, 128.14, 52.40, 42.21, 22.88, 21.71. LC-MS (ESI⁺): 379 (M + H)⁺.

(12a). The title compound was obtained as a solid from **7** and 4-chlorobenzylamine according to the general procedure in 78% yield. ¹H NMR (400 MHz, DMSO-d₆): δ 10.35 (br, 1H), 7.69 (m, 1H), 7.41-7.30 (m, 7H), 4.48 (d, 2H, *J* = 6.4 Hz), 3.46 (s, 2H), 2.21 (m, 4H), 1.29 (m, 6H). ¹³C NMR (100 MHz, DMSO-d₆): δ 168.30, 139.01, 137.29, 132.10, 132.03, 130.21, 129.96, 128.82, 128.06, 61.51, 53.32, 42.74, 40.67, 40.46, 40.25, 40.04, 39.83, 39.62, 25.74, 24.19. LC-MS (ESI⁺): 343 (M + H)⁺.

(12b). The title compound was obtained as a solid from **5** and benzylamine according to the general procedure in 71% yield. ¹H NMR (400 MHz, DMSO-d₆): δ 9.15 (m, 1H), 7.99 (m, 2H), 7.63 (m, 1H), 7.56 (m, 1H), 7.47 (m, 1H), 7.38 (m, 1H), 7.30 (m, 2H), 4.56 (s, 2H), 4.16 (s, 2H), 2.93 (br, 4H), 1.67 (br, 4H), 1.48 (br, 2H). ¹³C NMR (100 MHz, DMSO-d₆): δ 171.11, 144.77, 139.95, 133.85, 133.51, 132.50, 132.01, 58.72, 47.88, 28.12, 27.18. LC-MS (ESI⁺): 309 (M + H)⁺.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(12c). The title compound was obtained as a solid from **5** and 2-chlorobenzylamine according to the general procedure in 66% yield. ^1H NMR (400 MHz, DMSO- d_6): δ 9.15 (m, 1H), 7.99 (m, 2H), 7.63 (m, 1H), 7.56 (m, 1H), 7.47 (m, 1H), 7.38 (m, 1H), 7.30 (m, 2H), 4.56 (s, 2H), 4.16 (s, 2H), 2.93 (br, 4H), 1.67 (br, 4H), 1.48 (br, 2H). ^{13}C NMR (100 MHz, DMSO- d_6): δ 166.06, 136.21, 134.48, 131.96, 130.51, 130.43, 129.51, 129.13, 128.68, 128.64, 128.59, 127.54, 127.14, 78.82, 78.69, 52.32, 51.73, 40.09, 22.13. LC-MS (ESI $^+$): 343 (M + H) $^+$.

(12d). The title compound was obtained as a solid from **5** and 3-chlorobenzylamine according to the general procedure in 72% yield. ^1H NMR (400 MHz, DMSO- d_6): δ 10.10 (br, 1H), 9.32 (s, 1H), 8.00 (m, 2H), 7.68 (m, 1H), 7.57 (m, 1H), 7.37 (m, 4H), 4.51 (s, 2H), 4.35 (s, 2H), 3.32 (m, 2H), 2.89 (br, 4H), 1.68 (m, 5H), 1.35 (m, 1H). ^{13}C NMR (100 MHz, DMSO- d_6): δ 165.90, 142.11, 134.67, 134.10, 132.94, 130.53, 130.13, 130.02, 128.84, 127.11, 126.71, 125.98, 58.78, 51.78, 42.21, 22.31, 21.24. LC-MS (ESI $^+$): 343 (M + H) $^+$.

(12e). The title compound was obtained as a solid from **5** and 4-chlorobenzylamine according to the general procedure in 75% yield. ^1H NMR (400 MHz, DMSO- d_6): δ 9.11 (m, 1H), 7.88 (m, 2H), 7.63 (m, 1H), 7.51 (m, 2H), 7.39 (m, 4H), 4.47 (m, 2H), 3.37 (m, 2H), 2.66 (m, 2H), 1.58 (m, 6H), 1.25 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6): δ 166.54, 139.16, 134.87, 131.80, 129.63, 128.89, 128.70, 52.73, 42.54, 39.40, 23.51, 22.54. LC-MS (ESI $^+$): 343 (M + H) $^+$.

(12f). The title compound was obtained as a solid from **3** and 2-chlorobenzylamine according to the general procedure in 72% yield. ^1H NMR (400 MHz, DMSO- d_6): δ 9.31 (br, 1H), 9.12 (m, 1H), 8.01 (m, 2H), 7.62 (m, 2H), 7.47 (m, 1H), 7.33 (m, 3H), 4.56 (m, 2H), 4.34 (s, 2H), 2.88 (m, 2H), 1.82 (m, 2H), 1.63 (m, 3H), 1.38 (m, 1H). ^{13}C NMR (100 MHz, DMSO- d_6): δ 166.24, 136.69, 132.50, 131.79, 129.66, 129.17, 129.13, 128.23, 127.64, 59.04, 52.46, 41.13, 22.86, 21.72. LC-MS (ESI $^+$): 343 (M +

1
2 H)⁺.
3
4

5 (12g). The title compound was obtained as a solid from 3 and 3-chlorobenzylamine according to the
6
7 general procedure in 81% yield. ¹H NMR (400 MHz, DMSO-d₆): δ 9.05 (m, 1H), 7.85 (m, 2H),
8
9 7.41-7.27 (m, 6H), 4.47 (m, 2H), 3.40 (m, 2H), 2.33 (m, 4H), 1.40 (m, 6H). ¹³C NMR (100 MHz,
10
11 DMSO-d₆): δ 166.62, 142.83, 133.41, 130.65, 127.67, 127.50, 127.15, 126.38, 54.29, 42.60. LC-MS
12
13 (ESI⁺): 343 (M + H)⁺.
14
15
16

17
18 (12h). The title compound was obtained as a solid from 3 and 3-bromobenzylamine according to the
19
20 general procedure in 65% yield. ¹H NMR (400 MHz, DMSO-d₆): δ 9.04 (m, 1H), 7.84 (m, 2H),
21
22 7.50-7.29 (m, 6H), 4.46 (m, 2H), 3.46 (s, 2H), 2.31 (m, 4H), 1.50-1.38 (m, 6H). ¹³C NMR (100 MHz,
23
24 DMSO-d₆): δ 166.64, 143.13, 142.85, 133.16, 130.96, 130.41, 130.05, 129.02, 127.62, 126.79, 122.05,
25
26 62.88, 54.40, 42.55, 26.05, 24.44. LC-MS (ESI⁺): 389 (M + H)⁺.
27
28
29

30
31 (13a). The title compound was obtained as a solid from 5 and 3-methoxybenzylamine according to the
32
33 general procedure in 72% yield. ¹H NMR (400 MHz, CDCl₃): δ 7.78 (m, 1H), 7.74 (m, 1H), 7.46 (m,
34
35 1H), 7.38 (m, 1H), 7.29 (m, 1H), 6.97 (m, 1H), 6.92 (m, 1H), 6.84 (m, 1H), 6.65 (s, 1H), 4.62 (d, 2H, *J*
36
37 = 6.0 Hz), 3.81 (s, 3H), 3.60 (s, 2H), 3.49 (s, 2H), 2.49 (br, 4H), 1.55 (m, 3H), 1.37 (m, 1H). ¹³C
38
39 NMR (100 MHz, DMSO-d₆): δ 166.22, 159.24, 141.30, 134.20, 131.63, 129.30, 128.05, 127.70,
40
41 125.69, 119.37, 112.95, 111.97, 62.61, 54.91, 53.85, 42.53, 25.47, 23.93. LC-MS (ESI⁺): 339 (M +
42
43
44
45
46
47 H)⁺.
48
49

50 (13b). The title compound was obtained as a solid from 5 and 4-methoxybenzylamine according to the
51
52 general procedure in 68% yield. ¹H NMR (400 MHz, DMSO-d₆): δ 9.27 (br, 1H), 9.07 (m, 1H), 8.03
53
54 (d, 1H, *J* = 6.0 Hz), 7.97 (d, 1H, *J* = 6.0 Hz), 7.64 (d, 1H, *J* = 6.0 Hz), 7.58 (d, 1H, *J* = 6.0 Hz), 7.26 (m,
55
56 2H), 6.90 (m, 2H), 4.43 (d, 2H, *J* = 4.8 Hz), 4.33 (d, 2H, *J* = 3.6 Hz), 3.46 (s, 3H), 3.32 (m, 2H), 2.89
57
58
59
60

(m, 2H), 1.68 (m, 2H), 1.63 (m, 3H), 1.35 (m, 1H). ^{13}C NMR (100 MHz, DMSO- d_6): δ 165.55, 158.22, 134.98, 134.02, 131.41, 130.67, 129.93, 128.79, 128.67, 127.87, 113.67, 58.86, 55.05, 51.91, 42.13, 22.38, 21.24. LC-MS (ESI+): 339 (M + H) $^+$.

(**13c**). The title compound was obtained as a solid from **5** and 3-trifluoromethyl benzylamine according to the general procedure in 68% yield. ^1H NMR (400 MHz, DMSO- d_6): δ 9.13 (m, 1H), 7.79 (m, 2H), 7.66 (m, 4H), 7.44 (m, 2H), 4.56 (d, 2H, $J = 4.4$ Hz), 3.46 (s, 2H), 2.31 (br, 4H), 1.49 (m, 4H), 1.37 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6): δ 166.40, 141.23, 139.02, 133.96, 131.77, 131.45, 129.37, 128.13, 127.63, 125.70, 123.76, 123.73, 123.51, 123.48, 62.61, 53.88, 42.24, 25.50, 23.96. LC-MS (ESI+): 377 (M + H) $^+$.

(**13d**). The title compound was obtained as a solid from **5** and 4-trifluoromethyl benzylamine according to the general procedure in 74% yield. ^1H NMR (400 MHz, DMSO- d_6): δ 9.15 (m, 1H), 7.80 (m, 2H), 7.70 (m, 2H), 7.54 (m, 2H), 7.41 (m, 2H), 4.56 (s, 2H), 3.45 (s, 2H), 2.31 (br, 4H), 1.49 (m, 4H), 1.38 (m, 2H). ^{13}C NMR (100 MHz, DMSO- d_6): δ 166.35, 144.61, 139.00, 133.92, 131.78, 128.12, 127.87, 127.69, 125.73, 125.19, 125.17, 125.14, 125.10, 62.64, 53.89, 42.32, 35.49, 23.96. LC-MS (ESI+): 377 (M + H) $^+$.

2. Cell culture

INS-1 cells were cultured in RPMI 1640 (Corning, NY, USA) supplemented with 10% FBS (Atlanta Biologicals, Norcross, GA), HEPES (10 mM, Life Technologies, CA, USA), sodium pyruvate (1 mM, Corning), 2-mercaptoethanol (50 μM , Sigma, St Louis, MO, USA) and antibiotics (100 UI/mL penicillin and 100 $\mu\text{g}/\text{mL}$ streptomycin, Corning). βTC6 cells were cultured in DMEM (Corning) with 15% FBS, sodium pyruvate (1 mM, Corning), non-essential amino acids (1 mM, Thermo, IL, USA),

1
2 GlutaMAX (1 mM, Life Technologies) and antibiotics (100 UI/mL penicillin and 100 μ g/mL
3
4 streptomycin). All cells were grown at 37 °C in a humidified 5% CO₂ atmosphere.
5
6
7
8
9

10 **3. Cell survival assay**

11
12 INS-1 cells or β TC6 cells were seeded at 3×10^3 cells/well in a 384-well plate and treated with
13
14 compounds at the indicated concentrations. After 3 d treatment, the medium was aspirated and 20
15
16 μ L/well of CellTiter-Glo reagent (Promega, WI, USA) was added for the detection of intracellular ATP
17
18 levels. Cell viability was measured with an EnVision multilabel plate reader (PerkinElmer, MA, USA).
19
20
21 Three replicate wells per condition were performed in each experiment and three independent
22
23 experiments were performed.
24
25
26
27
28
29
30
31

32 **4. RNA isolation, RT-PCR and qRT-PCR**

33
34 INS-1 cells were seeded at 4×10^5 cells/well in 6-well plates and treated with compounds for the
35
36 indicated times. Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) according
37
38 to the manufacturer's protocol, and 2 μ g of total RNA was reverse transcribed using a Superscript kit
39
40 (Invitrogen). Real-time PCR was performed in 96-well format using SYBR Select Master Mix
41
42 (Applied Biosystems, Foster City, CA) with an ABI 7500 PCR system (Applied Biosystems). Relative
43
44 mRNA levels were normalized against the housekeeping gene Cyclophilin A and were determined by
45
46 $\Delta\Delta$ Ct calculated from the difference in Δ Ct values between the target gene and Cyclophilin A with and
47
48 without treatment, based on comparative CT (cycle threshold) method. Comparisons were performed
49
50 by two-tailed paired Student's *t*-test to obtain *P* values. Three replicate wells per condition were
51
52 performed in each experiment and three independent experiments were performed. The primer
53
54
55
56
57
58
59
60

1
2 sequences used were: Rat CHOP: F, 5'-GAAATCGAGCGCCTGACCAG-3' and R,
3
4 5'-GGAGGTGATGCCAACAGTTCA-3'. Rat ATF4: F, 5'- TCCTGAACAGCGAAGTGTTG-3' and R,
5
6 5'- GTGTCTGAGGCACTGACCAA-3'. Rat Bip: F, 5'-CTATTCCTGCGTCGGTGTATT-3' and R,
7
8 5'-GGTTGGACGTGAGTTGGTTCT-3'. Rat GRP94: F, 5'- TCCCCCTTAATGTTTCCCGTG-3' and
9
10 R, 5'-TAGCCCTTCTTCAGAAGCCTC-3'. Rat XBP1s: F, 5'- CTGAGTCCGAATCAGGTGCAG-3'
11
12 and R, 5'- ATCCATGGGAAGATGTTCTGG-3'. Rat XBP1 for regular PCR (XBP1u and XBP1s): F,
13
14 5'-GCTTGTGATTGAGAACCAGG-3', R, 5'-GAAAGGGAGGCTGGTAAGGAAC-3'. Rat Ins1: F,
15
16 5'- GTCCTCTGGGAGCCCAAG-3' and R, 5'- ACAGAGCCTCCACCAGG-3'. Rat Ins2: F, 5'-
17
18 ATCCTCTGGGAGCCCCGC-3' and R, 5'- AGAGAGCTTCCACCAAG-3'. Rat PDX1: F,
19
20 5'-GAGGACCCGTACAGCCTACA-3' and R, 5'- CGTTGTCCCGCTACTACGTT-3'. Rat MafA: F,
21
22 5'- AGCGGTCATATTTTCGCAAC-3' and R, 5'- CTCTACAGGGAGCAGCGAAC-3'. Rat
23
24 Cyclophilin A: F, 5'-GGTGACTTCACACGCCATAA-3' and R,
25
26 5'-CTTCCCAAAGACCACATGCT-3'.
27
28
29
30
31
32
33
34
35
36
37
38
39

40 5. Western blotting

41
42 INS-1 cells were seeded in 60-mm dishes at 8×10^5 cells/dish and treated for the indicated times. Cells
43
44 were then washed with PBS and lysed with lysis buffer (Cell Signaling Technology, Danvers, MA)
45
46 containing EDTA (Thermo, IL) and phosphatase inhibitors (Thermo). Aliquots of 20 μ g total protein
47
48 were separated on 7% SDS-PAGE gels (Life Technologies) and transferred to PVDF membranes (Life
49
50 Technologies). The membranes were probed with primary antibodies followed by the appropriate
51
52 HRP-conjugated secondary antibodies (goat anti-rabbit IgG and goat anti-mouse IgG, 1:3000; Santa
53
54 Cruz Biotechnology, CA, USA). Blots were then developed. Three independent experiments were
55
56
57
58
59
60

1
2 performed. The primary antibodies and dilutions used were: CHOP (1:1000, MA1-250, Thermo), ATF4
3
4 (1:1000, 10835-1-AP, ProteinTech Group, IL, USA), cleaved caspase 3 (1:1000, 9661, Cell Signaling
5
6 Technology, MA, USA), PARP (1:1000, 9542L, Cell Signaling Technology), and α -tubulin (1:3000,
7
8 SC-8035, Santa Cruz Biotechnology).
9
10

11 12 13 14 15 16 **6. MTT assay**

17
18 INS-1 cells or β TC6 cells were seeded at 3×10^3 cells/well in a 384-well plate and treated with
19
20 compounds at the indicated concentrations. After 3 d treatment, the medium was aspirated and 10 μ l of
21
22 MTT reagent (Cayman Chemical, MI, USA, prepared according to manufacturer's instruction) to each
23
24 well was added and mixed gently for one minute on an orbital shaker. The cells were then incubated for
25
26 three hours at 37 °C in a CO₂ incubator. After incubation, add 100 μ l of crystal dissolving solution to
27
28 each well, and incubate for 4 hours in a 37 °C CO₂ incubator. Viability will be measured for the
29
30 absorbance to each sample at 570 nm using EnVision multilabel plate reader (PerkinElmer, MA, USA).
31
32 Three replicate wells per condition were performed in each experiment and three independent
33
34 experiments were performed.
35
36
37
38
39
40
41
42
43
44
45
46

47 48 **7. Glucose-stimulated insulin secretion**

49
50 INS-1 or primary human islet cells were plated in 96-well plates. The second day, Tm and test
51
52 compound were added and maintained for 24 h (INS-1) or 48 h (human islets). Cells were then
53
54 incubated in fresh KRBH buffer (115 mM NaCl, 5 mM KCl, 24 mM NaHCO₃, 2.5 mM CaCl₂, 1 mM
55
56 MgCl₂, 10 mM HEPES, 2% w/v BSA, pH 7.4) containing 2.5 mM glucose for 1 h. Cells were
57
58
59
60

1
2 incubated for an additional hour in KRBH buffer containing 2.5, 25 (for INS-1 cells), or 20 (for human
3
4 islets) mM glucose. The secreted insulin was measured with insulin ELISA kits (for mouse insulin
5
6 from Millipore and for human insulin from LifeTech). Cells were lysed with RIPA buffer (50 mM Tris
7
8 HCl pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl), and total cellular protein was
9
10 determined with a Bradford protein assay. The secreted insulin levels were corrected for total protein.
11
12 Three replicate wells per condition were performed in each experiment and three independent
13
14 experiments were performed.
15
16
17
18
19
20
21
22
23
24
25

26 **8. Immunofluorescent and TUNEL Staining**

27
28 Primary human islets were washed with PBS and fixed with 4% paraformaldehyde for 30 min. Fixed
29
30 cells were then blocked in 5% normal donkey serum for 30 min. 50 islets per condition were used in
31
32 each experiment and three independent experiments were performed. Polyclonal guinea pig
33
34 anti-insulin (A0564, Dako, 1:500 dilution) was used as primary antibody. Donkey Cy3 anti-guinea pig
35
36 IgG was used as the secondary antibody. TUNEL staining was performed with In Situ Cell Death
37
38 Detection Kit-Fluorescein (Roche) according to the manufacturer's instructions. DAPI was used for
39
40 nuclear counter-staining. Images were taken with an Olympus FV1000 confocal microscope.
41
42
43
44
45
46
47
48
49

50 **9. Animal study**

51
52 All procedures involving animals were performed in accordance with the protocol approved by the
53
54 University of Oklahoma Health Science Center Institutional Animal Care and Use Committee
55
56 (IACUC). C57BL/6 mice were obtained from The Jackson Laboratory (Bar Harbor, Maine) and
57
58
59
60

1
2 maintained on a 12 h light (6:00 AM-6:00 PM)-12 h dark (6:00 PM-6:00 AM) cycle at an ambient
3
4 temperature of 21°C. Mice were given free access to water and food. All experiments were performed
5
6 with age-matched male mice. Compounds were dosed approximately 3~4 hours before the initiation of
7
8 the dark cycle (2~3 PM during the light cycle). For streptozotocin (STZ)-induced diabetic model,
9
10 ten-week-old C57BL/6 mice were injected intraperitoneally (i.p.) once daily for five days with STZ
11
12 (dissolved in Na-Citrate Buffer; 50 mg/kg) and either **13d** (5 mg/kg body weight; 2 mg/ml in 10%
13
14 DMSO in saline buffer; $n = 7$ mice) or vehicle ($n = 6$ mice). Injections of vehicle or **13d** alone were
15
16 then continued for 2 more weeks. Every third day, animals were fasted for 5 h and blood was obtained
17
18 by tail snip. Blood glucose levels were measured using a glucometer (Nova Statstrip Xpress; Data
19
20 Science International, St. Paul, MN). At the end of the treatment period, mice were sacrificed and the
21
22 pancreases were removed, fixed in formalin, and paraffin-embedded. Tissue blocks were serially
23
24 sectioned at intervals of 100 μm and 6 sections were stained with an anti-insulin antibody (A0564,
25
26 1:500 dilution; Dako), anti-glucagon antibody (G2654, 1:500 dilution; Sigma), and DAPI (0.5 $\mu\text{g/ml}$).
27
28 Insulin-positive cells were used to demarcate islets, and the total islet area was measured with an
29
30 Olympus FV1000 confocal microscopy and quantified with Image-J histogram software.
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **10. Statistical analysis**

46
47 Data are presented as means \pm SD unless specified. Comparisons were performed by two-tailed paired
48
49 Student's *t*-test. A *P* value of <0.05 was considered statistically significant.
50
51
52
53
54
55
56
57
58
59
60

1
2 **AUTHOR INFORMATION**
3

4 *Corresponding Author: Weidong-wang@ouhsc.edu
5
6
7
8
9

10 **NOTES**
11

12 The authors declare no competing financial interests.
13
14

15 **ACKNOWLEDGMENTS**
16

17 This work was supported by Oklahoma Center for the Advancement of Science and Technology and
18 National Institutes of Health (GM103636, DK108887) to W.W.
19
20
21
22
23
24
25

26 **ABBREVIATIONS USED**
27

28 ER, endoplasmic reticulum; UPR, unfolded protein response; INS-1 cell, rat insulinoma cell line; Tm,
29 tunicamycin; SAR, structure-activity relationship; EC₅₀, half maximal effective concentration; THF,
30 tetrahydrofuran; DIEA, *N,N*-diisopropylethylamine; RT-PCR, reverse transcription polymerase chain
31 reaction; TUNEL, Terminal deoxynucleotidyl transferase dUTP nick end labeling; PARP,
32 Poly(ADP-ribose) polymerase; PERK, PKR-like ER kinase; eIF2 α , eukaryotic translation initiator
33 factor 2 α ; ATF4, activating transcription factor 4; CHOP, C/EBP homologous protein; XBP1, X-box
34 binding protein 1; ATF6, activating transcription factor 6; FBS, fetal bovine serum; PDX1, pancreatic
35 and duodenal homeobox 1; MafA, v-maf musculoaponeurotic fibrosarcoma oncogene family, protein A;
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

56 **Supporting Information**
57

58 The purities of the synthesized final compounds and molecular formula strings of compounds. This
59
60

1
2 material is available free of charge via the Internet at <http://pubs.acs.org>.
3
4
5
6

7 **References:**

- 8
9
10 1. Vetere, A.; Choudhary, A.; Burns, S. M.; Wagner, B. K. Targeting the Pancreatic Beta-Cell to Treat Diabetes. *Nat. Rev. Drug Discovery* **2014**, *13*, 278-289.
- 11
12 2. Donath, M. Y.; Halban, P. A. Decreased Beta-Cell Mass in Diabetes: Significance, Mechanisms and Therapeutic Implications. *Diabetologia* **2004**, *47*, 581-589.
- 13
14 3. Prentki, M.; Nolan, C. J. Islet Beta Cell Failure in Type 2 Diabetes. *J. Clin. Invest.* **2006**, *116*, 1802-1812.
- 15
16 4. Fonseca, S. G.; Gromada, J.; Urano, F. Endoplasmic Reticulum Stress and Pancreatic Beta-Cell Death. *Trends Endocrinol. Metab.: TEM* **2011**, *22*, 266-274.
- 17
18 5. Scheuner, D.; Kaufman, R. J. The Unfolded Protein Response: A Pathway That Links Insulin Demand with Beta-Cell Failure and Diabetes. *Endocr. Rev.* **2008**, *29*, 317-333.
- 19
20 6. Back, S. H.; Kaufman, R. J. Endoplasmic Reticulum Stress and Type 2 Diabetes. *Annu. Rev. Biochem.* **2012**, *81*, 767-793.
- 21
22 7. Senft, D.; Ronai, Z. A. Upr, Autophagy, and Mitochondria Crosstalk Underlies the Er Stress Response. *Trends Biochem. Sci.* **2015**, *40*, 141-148.
- 23
24 8. Eizirik, D. L.; Cardozo, A. K.; Cnop, M. The Role for Endoplasmic Reticulum Stress in Diabetes Mellitus. *Endocr. Rev.* **2008**, *29*, 42-61.
- 25
26 9. Tersey, S. A.; Nishiki, Y.; Templin, A. T.; Cabrera, S. M.; Stull, N. D.; Colvin, S. C.; Evans-Molina, C.; Rickus, J. L.; Maier, B.; Mirmira, R. G. Islet Beta-Cell Endoplasmic Reticulum Stress Precedes the Onset of Type 1 Diabetes in the Nonobese Diabetic Mouse Model. *Diabetes* **2012**, *61*, 818-827.
- 27
28 10. Engin, F.; Yermalovich, A.; Nguyen, T.; Hummasti, S.; Fu, W.; Eizirik, D. L.; Mathis, D.; Hotamisligil, G. S. Restoration of the Unfolded Protein Response in Pancreatic Beta Cells Protects Mice against Type 1 Diabetes. *Sci. Transl. Med.* **2013**, *5*, 211ra156.
- 29
30 11. Papa, F. R. Endoplasmic Reticulum Stress, Pancreatic Beta-Cell Degeneration, and Diabetes. *Cold Spring Harbor Perspect. Med.* **2012**, *2*, a007666.
- 31
32 12. Hetz, C.; Chevet, E.; Harding, H. P. Targeting the Unfolded Protein Response in Disease. *Nat. Rev. Drug Discovery* **2013**, *12*, 703-719.
- 33
34 13. Bertolotti, A.; Zhang, Y.; Hendershot, L. M.; Harding, H. P.; Ron, D. Dynamic Interaction of Bip and Er Stress Transducers in the Unfolded-Protein Response. *Nat. Cell Biol.* **2000**, *2*, 326-332.
- 35
36 14. Schroder, M.; Kaufman, R. J. Er Stress and the Unfolded Protein Response. *Mutat. Res.* **2005**, *569*, 29-63.
- 37
38 15. Walter, P.; Ron, D. The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation. *Science* **2011**, *334*, 1081-1086.
- 39
40 16. Tabas, I.; Ron, D. Integrating the Mechanisms of Apoptosis Induced by Endoplasmic Reticulum Stress. *Nat. Cell Biol.* **2011**, *13*, 184-190.
- 41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17. Duan, H.; Lee, J. W.; Moon, S. W.; Arora, D.; Li, Y.; Lim, H. Y.; Wang, W. Discovery, Synthesis, and Evaluation of 2,4-Diaminoquinazolines as a Novel Class of Pancreatic Beta-Cell-Protective Agents against Endoplasmic Reticulum (Er) Stress. *J. Med. Chem.* **2016**, *59*, 7783-7800.
 18. Tran, K.; Li, Y.; Duan, H.; Arora, D.; Lim, H. Y.; Wang, W. Identification of Small Molecules That Protect Pancreatic Beta Cells against Endoplasmic Reticulum Stress-Induced Cell Death. *ACS Chem. Biol.* **2014**, *9*, 2796-2806.
 19. Van Lommel, L.; Janssens, K.; Quintens, R.; Tsukamoto, K.; Vander Mierde, D.; Lemaire, K.; Deneff, C.; Jonas, J. C.; Martens, G.; Pipeleers, D.; Schuit, F. C. Probe-Independent and Direct Quantification of Insulin Mrna and Growth Hormone Mrna in Enriched Cell Preparations. *Diabetes* **2006**, *55*, 3214-3220.
 20. Schuit, F. C.; In't Veld, P. A.; Pipeleers, D. G. Glucose Stimulates Proinsulin Biosynthesis by a Dose-Dependent Recruitment of Pancreatic Beta Cells. *Proc. Natl. Acad. Sci. U. S. A.* **1988**, *85*, 3865-3869.
 21. Ladriere, L.; Igoillo-Esteve, M.; Cunha, D. A.; Brion, J. P.; Bugliani, M.; Marchetti, P.; Eizirik, D. L.; Cnop, M. Enhanced Signaling Downstream of Ribonucleic Acid-Activated Protein Kinase-Like Endoplasmic Reticulum Kinase Potentiates Lipotoxic Endoplasmic Reticulum Stress in Human Islets. *J. Clin. Endocrinol. Metab.* **2010**, *95*, 1442-1449.
 22. Cnop, M.; Ladriere, L.; Hekerman, P.; Ortis, F.; Cardozo, A. K.; Dogusan, Z.; Flamez, D.; Boyce, M.; Yuan, J.; Eizirik, D. L. Selective Inhibition of Eukaryotic Translation Initiation Factor 2 Alpha Dephosphorylation Potentiates Fatty Acid-Induced Endoplasmic Reticulum Stress and Causes Pancreatic Beta-Cell Dysfunction and Apoptosis. *J. Biol. Chem.* **2007**, *282*, 3989-3997.
 23. Slee, E. A.; Harte, M. T.; Kluck, R. M.; Wolf, B. B.; Casiano, C. A.; Newmeyer, D. D.; Wang, H. G.; Reed, J. C.; Nicholson, D. W.; Alnemri, E. S.; Green, D. R.; Martin, S. J. Ordering the Cytochrome C-Initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9-Dependent Manner. *J. Cell Biol.* **1999**, *144*, 281-292.
 24. Herceg, Z.; Wang, Z. Q. Functions of Poly(Adp-Ribose) Polymerase (Parp) in DNA Repair, Genomic Integrity and Cell Death. *Mutat. Res.* **2001**, *477*, 97-110.
 25. Rutter, G. A.; Pullen, T. J.; Hodson, D. J.; Martinez-Sanchez, A. Pancreatic Beta-Cell Identity, Glucose Sensing and the Control of Insulin Secretion. *Biochem. J.* **2015**, *466*, 203-218.
 26. Kataoka, K.; Han, S. I.; Shioda, S.; Hirai, M.; Nishizawa, M.; Handa, H. Mafk Is a Glucose-Regulated and Pancreatic Beta-Cell-Specific Transcriptional Activator for the Insulin Gene. *J. Biol. Chem.* **2002**, *277*, 49903-49910.
 27. Wang, S.; Kaufman, R. J. The Impact of the Unfolded Protein Response on Human Disease. *J. Cell Biol.* **2012**, *197*, 857-867.
 28. Ahn, C.; An, B.-S.; Jeung, E.-B. Streptozotocin Induces Endoplasmic Reticulum Stress and Apoptosis Via Disruption of Calcium Homeostasis in Mouse Pancreas. *Mol. Cell. Endocrinol.* **2015**, *412*, 302-308.
 29. Zhang, R.; Kim, J. S.; Kang, K. A.; Piao, M. J.; Kim, K. C.; Hyun, J. W. Protective Mechanism of Kiom-4 in Streptozotocin-Induced Pancreatic Beta-Cells Damage Is Involved in the Inhibition of Endoplasmic Reticulum Stress. *Evid. Based Complement Alternat. Med. : eCAM* **2011**, *2011*.

